However, more research is needed to confirm these results and make any statements about dosages. Black pepper is a crucial ingredient in golden milk because it increases the bioavailability of ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

An independent data monitoring committee (DMC) favors continuing dosing Elevidys (delandistrogene moxeparvovec-rokl) to people with Duchenne muscular dystrophy (DMD) in ongoing clinical trials, ...

Michael Buble says Canada is 'not for sale,' at the Juno Awards, setting the tone for a night of references to Canada’s current tensions with the U.S.

Chondroitin sulfate is a relatively safe supplement used to support joint and cartilage health. Chondroitin sulfate has become increasingly popular for managing joint pain, particularly related to ...

dosing—compared to weekly or even daily injections currently on the market. This first-in-class therapy works by reducing antithrombin, a protein that delays blood clotting, and significantly ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with ...

The prescribed dosage for ondansetron may vary depending on a person’s individual treatment plan. Factors such as your medical history and other medications you take may also affect your dosage ...

Nonactive SPMS patients ages 18-75 are being recruited at five sites. “We are pleased to announce dosing at Yale in our multicenter Phase 2 trial, an important milestone in our efforts to ...